Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis
Momelotinib provides a more favorable safety profile and a higher chance for hemoglobin improvement vs pacritinib.
Authors
- Francesca Palandri (ORCID: https://orcid.org/0000-0001-8367-5668)
- Boris Gorsh (ORCID: https://orcid.org/0000-0001-6977-0220)
- Catherine Elizabeth Ellis (ORCID: https://orcid.org/0009-0008-7635-7846)
- Ruben A. Mesa (ORCID: https://orcid.org/0000-0001-5880-7972)
- Claire N. Harrison (ORCID: https://orcid.org/0000-0002-3212-920X)
- Balázs Dobi (ORCID: https://orcid.org/0000-0002-1187-4104)
- Tom Liu
- Lucia Masárová (ORCID: https://orcid.org/0000-0001-6624-4196)
- Srđan Verstovšek (ORCID: https://orcid.org/0000-0002-6912-8569)
- Dwaipayan Patnaik
- Zhaohui Wang (ORCID: https://orcid.org/0000-0003-4357-9780)
- Venediktos V. Kapetanakis (ORCID: https://orcid.org/0000-0002-4147-0549)
Institutions
- Ithaka Harbors (US)
- The University of Texas MD Anderson Cancer Center (US)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Azienda USL di Bologna (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1080/14796694.2025.2511562
- Citations
- 2
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- GlaxoSmithKline